Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.
All month long, News 3 has been taking action for men's health, sharing stories from cancer survivors and advocates, while raising funds for the Movember Foundation. Wednesday, News 3 is wrapping up its Movember series talking about testicular cancer.
E-Mail
DURHAM, N.C. - A study designed to enroll an equal number of Black and white men with advanced prostate cancer confirms key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease.
Researchers at Duke Cancer Institute enrolled 50 Black and 50 white men with advanced prostate cancer to test whether there were outcome differences on treatment with the hormone therapy abiraterone acetate plus the steroid prednisone. In retrospective data reviews, the Duke researchers had previously found racial differences in PSA responses among advanced prostate cancer patients.